Diagnosing Balamuthia mandrillaris encephalitis via next-generation sequencing in a 13-year-old girl

Xia Wu a, Gangfeng Yan b, Shuzhen Han a, Yingzi Ye a, Xunjia Cheng c, Hairong Gong b and Hui Yu a

*Department of Infectious Diseases, Children’s Hospital of Fudan University, Shanghai, People’s Republic of China; bDepartment of Pediatric Emergency Medicine and Critical Care Medicine, Children’s Hospital of Fudan University, Shanghai, People’s Republic of China; cDepartment of Medical Microbiology and Parasitology, School of Basic Medical Sciences, Fudan University, Shanghai, People’s Republic of China

ABSTRACT

Balamuthia amoebic encephalitis has a subacute-to-chronic course and is almost invariably fatal owing to delayed diagnosis and a lack of effective therapy. Here, we report a 13-year-old girl with cutaneous lesions and multifocal granulomatous encephalitis. The patient underwent a series of tests and was suspected as having tuberculosis. She was treated with various empiric therapies without improvement. She was finally correctly diagnosed via next-generation sequencing of the cerebrospinal fluid. The patient deteriorated rapidly and died 2 months after being diagnosed with Balamuthia mandrillaris encephalitis. This study highlights the important clinical significance of next-generation sequencing, which provides better diagnostic testing for unexplained paediatric encephalitis, especially that caused by rare or emerging pathogens.

INTRODUCTION

Balamuthia mandrillaris, a free-living amoeba found in soil and water, causes encephalitis in humans, sheep, dogs, horses, and nonhuman primates. B. mandrillaris is likely transmitted via inhalation or inoculation through broken skin and spreads to the brain and other organs through haematogenesis. In 1990, B. mandrillaris became recognized as a pathogen that causes granulomatous amoebic encephalitis (GAE) in humans. To date, more than 200 cases of Balamuthia amoebic encephalitis (BAE) have been identified worldwide. The disease is usually fatal and is difficult to successfully treat. Here, for the first time in China, we treated a 13-year-old girl with cutaneous lesions and multifocal granulomatous encephalitis. The patient deteriorated rapidly and died 2 months after being diagnosed with B. mandrillaris encephalitis via next-generation sequencing (NGS).

RESULTS

Case report

A previously healthy 13-year-old girl presented in March 2019 with a two-year history of cutaneous lesions on her left thigh. Two years prior, she noticed several asymptomatic papules on her left thigh. The skin lesions slowly increased in size to form an erythematous plaque. Two years later, the lesion on her left thigh became enlarged and evolved into violaceous plaques (Figure 1). A topical steroid cream was administered for 4 weeks without resolution of the skin lesion. A tuberculin skin test was negative. A skin biopsy was performed at another institution in September 2018. Histopathologic examination revealed a granulomatous reaction rich in lymphocytes and was suspected to be tuberculosis. The patient began empirical therapy with rifampin and clarithromycin for 4 months, and the lesions improved.

One month after discontinuing the medication (Feb. 2019), she was taken to a hospital because of dizziness, vomiting, and blurry vision. A computed tomography scan of the brain revealed an area of hypodensity in the region of the left lateral ventricle and left occipital lobe (Figure 2). Three weeks later, the girl developed abnormal eye movements and diplopia. The patient was treated with antimicrobials, including isoniazid, rifampin, ceftazidime, and amikacin. The patient clinically deteriorated with worsening vomiting and headaches.

In March 2019, she was admitted to Children’s Hospital of Fudan University with symptoms of fever, vomiting, headaches, and a right esotropia. Cerebrospinal fluid (CSF) examination showed 100 × 10^6 white blood cells (CSF) examination showed 100 × 10^6
leukocytes/L (20% neutrophils, 80% lymphocytes), glucose of 1.6 mmol/L, and protein of 1467 mg/L. CSF cultures showed no bacteria or fungi. Infectious meningitis and encephalitis were suspected, and intravenous meropenem (4.5 g daily) and linezolid (1200 mg daily) were given without improvement.

Her CSF sample was sent to the Beijing Genomics Institute (BGI)-Wuhan for pathogen detection via NGS. Three days later, NGS of the CSF confirmed the presence of B. mandrillaris genomic sequences. One hundred sixty-five sequence copy reads corresponded to B. mandrillaris. No bacteria, fungi, viruses, Mycobacterium tuberculosis, or mycoplasma were detected via NGS of the CSF. B. mandrillaris was confirmed by polymerase chain reaction (PCR) of a skin sample (obtained from the skin biopsy in Sep. 2018) using the specific primers, BalaF1451 (TAACCTGCTAAATAGTCATGCCAAT) and BalaR1621 (CAAACTTCCCTCGGCTAATCA) (Figure 3). Immunostaining of serum and CSF samples obtained from the patient in Apr. 2019 yielded an Acanthamoeba antibody titre of 1:50–1:100 (Figure 4).

Antibacterial therapy was discontinued, and the patient was placed on a regimen of albendazole (400 mg daily), trimethoprim-sulfamethoxazole (TMP-SMX; 72 mg/kg/day in three divided doses), and azithromycin (10 mg/kg/day). The patient was admitted in April with fever, a headache, vomiting and chest tightness. Upon admission, she was treated with albendazole (400 mg once daily) and fluconazole (400 mg once daily) for 3 days, but her situation did not improve. Her treatment was changed to amphotericin B liposome, 5-fluorocytosine and TMP-SMX (Table 1). Her symptoms subsequently improved, and her fever waned (Figure 5).

On day 9 of her hospitalization, the patient developed chest tightness and ventricular fibrillation, due to severe cardiovascular adverse reactions of amphotericin B liposome, and was placed on a ventilator. She was transferred directly to the intensive care unit and administered therapy consisting of amphotericin B liposome, 5-fluorocytosine and fluconazole. She improved and was taken off the ventilator 4 days later. On day 22 of her hospitalization, treatment with amphotericin B liposome was discontinued as her renal function progressively worsened. She was transferred to the department of infectious diseases in stable condition on day 24. At this time, her symptoms worsened, and she developed progressive loss of muscle strength in the lower extremities. Magnetic resonance imaging scans of the spinal cord and head showed new lesions (Figure 6). Intravenous amphotericin B liposome and intrathecal amphotericin were added to the regimen. The patient was transferred to the

![Figure 1](image1.png)
**Figure 1.** A. Cutaneous lesion on the left observed in September 2018 showing an erythematous plaque; B. Cutaneous lesion on the left observed in March 2019; C. Cutaneous lesion on the left observed in April 2019 showing a crusty surface and scarring.

![Figure 2](image2.png)
**Figure 2.** Computed tomography scan of the brain revealed an area of hypodensity in the region of the left lateral ventricle and left occipital lobe.

![Figure 3](image3.png)
**Figure 3.** PCR amplification of Acanthamoeba and Balamuthia DNA using the specific primers, BalaF1451 and BalaR1621. M: 100-bp DNA ladder; Lane 1: negative control detecting Acanthamoeba; Lane 2: patient’s sample detecting Acanthamoeba; Lane 3: negative control detecting Balamuthia; Lane 4: patient’s sample detecting Balamuthia.
Amphotericin B 0.18
Amphotericin B 0.025
Rifampin 10 mg/kg/day once daily. PO 16 days
Fluorocytosine 100 mg/kg/day in four divided doses.
Fluconazole 400 mg once daily. IV 59 days
Albendazole 400 mg once daily.
Rifampin 10 mg/kg/day once daily.

Table 1. Recommended drug treatment for Balamuthia mandrillaris encephalitis.

| Drug            | Dose               | Route   | Duration |
|-----------------|--------------------|---------|----------|
| Amphotericin B  | 0.1–0.5 mg/kg/day| IV      | 36 days  |
| Liposome        | 1.5–2.5 mg/kg/day | IV      | 36 days  |
| Amphotericin B  | 0.18–0.25 mg/kg/day| IV      | 5 days   |
| Amphotericin B  | 0.025–0.05 mg/kg/day| IV      | 5 days   |
| TMP-SMX         | 30–36 mg/kg/day   | PO      | 24 days  |
| Albendazole     | 400 mg/kg/day     | PO      | 16 days  |
| Fluconazole     | 400 mg/kg/day     | IV      | 59 days  |
| Fluorocytosine  | 100 mg/kg/day     | PO      | 48 days  |

Note: Acronyms: IV-Intravenous; PO-Oral Therapy.

intensive care unit because her neurological status had deteriorated. She soon became unable to breathe and was placed on a ventilator. Unfortunately, her symptoms did not improve, and she went into a deep coma with a Glasgow Coma Scale score of 3. On day 64, the patient went into cardiac arrest and was given cardiopulmonary resuscitation. The next day, the patient was returned to Quan-Zhou Hospital at the request of her parents. Two weeks later, given the poor prognosis, her family decided to cease medical treatment, and she was pronounced dead.

The patient had no predisposing immunosuppression. Her whole-genome sequencing results were normal, and she denied any history of drinking river water or consuming raw meat.

Discussion

Free-living amoebas are widely disseminated in the environment worldwide. Four genera of amoebas infect the central nervous system (CNS) in humans: Naegleria, Acanthamoeba, Balamuthia, and Sappinia [1]. Two CNS clinical syndromes are associated with free-living amoebas: primary amebic meningoencephalitis (PAM) and GAE. PAM, caused by N. fowleri, is an acute haemorrhagic meningoencephalitis. GAE, caused by Acanthamoeba spp., B. mandrillaris, and Sappinia pedata, is a rare subacute-chronic infection of the CNS.

The first infection of B. mandrillaris was reported in a pregnant mandrill baboon in the San Diego Wild Animal Park in 1989 [2]. Cases of human infections have been reported since 1990. To date, 30 cases of BAE have been identified in children worldwide (Table 2). BAE is almost always fatal because of delayed diagnosis and a lack of effective therapy. B. mandrillaris can be isolated from water and soil worldwide. Its life cycle comprises two stages: trophozoites and cysts. Trophozoites are the infective form and can infect humans via the skin or lungs and spread to the brain and other organs via haematogenesis [24,25]. Increasing numbers of organ transplant-transmitted B. mandrillaris show that it can be transmitted through organ transplantation [26,27]. B. mandrillaris most likely accesses the CNS through the blood-brain barrier (BBB). Jayasekera et al. showed that B. mandrillaris activates human brain microvascular endothelial cells to release high levels of interleukin (IL)-6 cytokines, and this host inflammatory response may play an important role in traversing the BBB [28]. B. mandrillaris causes infections primarily in immunocompromised persons but also in immunocompetent hosts, especially children [29]. Risk factors include a young age, Hispanic ethnicity, and exposure to contaminated soil or water [30]. The girl in our report was not immunosuppressed and she had history of playing barefoot on the beach during the summer.

BAE has a subacute-to-chronic course, and fewer than 10% of patients survive. BAE is difficult to diagnose because it lacks characteristic clinical symptoms, laboratory and neuroimaging findings. B. mandrillaris primarily affects two organ systems in humans: the skin and the CNS. The most common clinical features include fever, headache, vomiting, altered mental status, weakness, and seizures [31]. In some cases, cutaneous lesions precede BAE [12]. The United States case series reported that only 5% of patients had a cutaneous form of the disease [31], whereas majority of patients presented with a cutaneous lesion initially in the Peruvian case series [32]. Skin lesions may lead to an earlier diagnosis and treatment and may prevent progression to BAE. Unfortunately, many cases of BAE are diagnosed postmortem via autopsy or immunostained sections of the skin or brain tissue [31].

CSF specimens from patients with BAE have mildly elevated white blood cell counts with lymphocytes.
Figure 5. Clinical course of a 13-year-old girl with Balamuthia mandrillaris encephalitis. Graph A shows the body-temperature curve (red line) and peripheral-blood leukocyte counts (blue bars). Graph B shows the leukocyte count and differential (bars) and the protein (solid line) and glucose (dashed line) levels from cerebrospinal fluid samples. Graphs C and D show the liver and kidney function and serum electrolyte levels in serially collected blood samples. ALT: alanine aminotransferase; AST: aspartate aminotransferase; CR: creatinine.
Figure 6. A, Axial T1-weighted enhanced image (March 28, 2019) showing multiple enhanced lesions throughout the brain, including the parietal lobe, left temporal lobe and occipital, and cerebellum. B, C, Axial T1-weighted images (April 13, 2019). D–F, Axial T2-weighted images (tirm dark fluid) (April 13, 2019) showing larger areas of multiple enhanced nodular lesions. G, Axial T1-weighted image (April 26, 2019). H, Axial T2-weighted image (tirm dark fluid) (April 26, 2019) showing new patchy lesions in the right frontal region. I–L, T1-weighted images (May 8, 2019) of the spinal cord and head showing new patchy lesions in the cervical and thoracic regions.
predominating, slightly low or normal glucose, and elevated or normal protein. Infected CSF resembles that of viral encephalitis or aseptic meningitis. CSF specimens from patients with BAE have significantly elevated levels of IL-6 and IL-8 [33]. In the CSF of patients with BAE, Balamuthia is rarely detected microscopically or by PCR; most patients are diagnosed via brain biopsy [31]. Neuroimaging findings can be uncharacteristic of BAE, including oedema, enhanced lesions, and multifocal lesions. The lesions can be located throughout the brain in no particular region and vary in size. The differential diagnoses for BAE include neurotuberculosis, neurocysticercosis, fungal infections, neoplasms, viral meningoencephalitis, and acute disseminated encephalomyelitis [5].

_B. mandrillaris_ treatment is rarely studied. Owing to successful use in surviving patients, pentamidine, sulfadiazine, fluconazole, flucytosine, clarithromycin, azithromycin, and miltefosine (now available commercially in the US) antimicrobials (alone or in combination) are recommended for treating Balamuthia infections. Miltefosine is an antileishmanial
and antineoplastic agent, which has been effective in treating patients with BAE. A recent study demonstrated that nitroxoline may be an important new treatment for *B. mandrillaris* [34]. Because of the difficulty in diagnosing BAE and the resultant delay in initiating antimicrobial therapy, majority of patients died in a short period after diagnosis of BAE. We review the previously reported cases of infections due to *Balamuthia mandrillaris* in children (Table 2). So far, only 1 child with BAE are reported to have survived. This patient presented with fever, generalized seizures, and MRI findings of edema in the left temporal area of the brain. A CT-guided brain biopsy was performed 19 days after initial presentation. Examination revealed acute suppurative and necrotizing inflammation, and structures consistent with amoebas, which were identified as *B. mandrillaris* by indirect immunofluorescence staining. The patient was treated with clarithromycin, flucytosine, and thioridazine. And the patient remained stable, and had no gross neurologic sequelae. The diagnosis and antimicrobial therapy were initiated early enough to halt the course of disease, leading to survival of this girl. In our case, the immunocompetent patient had a two-year history of cutaneous lesions on her left thigh. Despite various empiric therapies, the skin lesions progressed to neurologic symptoms. Because of the late diagnosis, treatment was ineffective, and the patient died soon after being conclusively diagnosed with BAE. Early diagnosis and treatment are essential to increase the chances of survival.

*B. mandrillaris* is difficult to culture. Skin biopsies should be performed, and common histopathologic characteristics include diffuse granulomatous reactions on the reticular dermis, surrounding infiltration rich in lymphocytes and plasma cells, and multinucleated giant cells. Brain biopsies typically demonstrate perivascular and granulomas with foamy macrophages and multinucleated giant cells accompanied by lymphocytes. Definitive diagnosis requires visualizing a trophozoite or cyst [35]. In the Peruvian cases, amebic trophozoites may be seen in two-thirds of the skin biopsies [32]. But the amebic trophozoites were scarce in number, and were difficult to identify. Differentiation of trophozoites from histiocytes requires experience in recognizing the characteristic of these parasites. In the United States case series, 18% (2/11) of cases with *Balamuthia* infections showed trophozoites in the meninges. None showed cysts in the meninges [35]. Because of low trophozoite and cyst densities, indirect immunofluorescence and PCR assays have been developed to rapidly identify BAE [36,37]. Nevertheless, in most countries, the lack of availability of indirect immunofluorescence and PCR tests for *B. mandrillaris* limits the opportunity for diagnosis. As shown in our case, BAE is difficult to diagnose in patients lacking typical symptoms, laboratory or neuroimaging findings. Our patient underwent a series of tests and was treated with various empiric therapies without improvement. She was finally correctly diagnosed via NGS of the CSF.

NGS may make it easier to diagnose difficult-to-diagnose infections, although the pan-pathogen detection technique has limitations in determining the sensitivity or detection limit for all organisms. NGS is especially suitable for difficult cases, and NGS of clinical samples can help diagnose complicated infectious diseases of atypical, rare, and novel aetiologies. Increasing microbes have been identified via NGS since its advent in 2004 [4,38–40], including *S. erinaceieuropaei, Taenia solium,* and nontuberculous mycobacterium. The samples for NGS analysis are generally flexible, including Cerebrospinal fluid, respiratory secretions, blood, pleural effusion, ascites, tissue, etc. The current cost of NGS is higher (3000 Ren Min Bi [RMB]) than culture test. The turnaround time is under 48 hours, significantly faster than that of pathogen cultures [41], and is less affected by prior antibiotic exposure.

Encephalitis causes significant mortality worldwide, and more than 50% of cases have no identified etiology [38]. NGS of the CSF may guide timelier diagnoses and more targeted treatments for encephalitis of unknown origin, which may improve clinical outcomes. NGS is an unbiased and rapid approach, which can detect all pathogens in a sample. In the UK cases, the diagnostic yield for NGS in encephalitis is 50%. Brown et al. [42] reviewed 44 undiagnosed cases of encephalitis in which NGS provided diagnosis. In 28 of the 44 cases, novel, rare or unexpected organisms were detected which are unlikely to have been detected using specific PCR assays. In a multicenter, prospective study [43], Wilson et al reported that among 58 infections of the nervous system, NGS identified 13 (22%) that were not identified by conventional testing, and NGS made concurrent diagnoses in 19. A total of 8 of these 13 diagnoses made solely by NGS had a clinical effect, with guiding treatment in 7 cases.

In the field of amoebic encephalitis, NGS are now available for diagnosis of *Acanthamoeba castellani, N. fowleri* [44], and *Balamuthia mandrillaris*. The reports concerning the use of NGS for diagnosis of amoebic encephalitis are comprised of single case reports. In 2008, Wang Q et al. [45] reported a case of PAM disease, which was successfully detected *N. fowleri* in the CSF specimen via NGS. *N. fowleri* infection was subsequently confirmed by PCR. In 2015, Greninger et al. [46] successfully detected *Balamuthia mandrillaris* in a Brain Biopsy specimen via NGS. Wilson et al. [47] identified *Balamuthia mandrillaris* in the CSF of a patient with undiagnosed encephalitis via NGS. Subsequently, PCR confirmed the presence of *B. mandrillaris* in CSF and brain tissue. Our patient was finally correctly diagnosed with
Balamuthia mandrillaris encephalitis via NGS of the CSF. B. mandrillaris was confirmed by PCR of a skin sample and immunostaining of serum and CSF samples. Because of the late diagnosis, the skin lesions progressed to neurologic symptoms, and the patient died soon after being conclusively diagnosed with BAE. In fact, treatment was not effective in our patients, mainly because of the late diagnosis. NGS of CSF is likely to significantly improve the early diagnosis of neurologic infections, leading to better outcomes.

In summary, BAE carries a high mortality rate owing to its difficult diagnosis and delayed effective therapy. BAE should be considered in patients with subacute or chronic granulomatous meningoencephalitis, especially with skin lesions, when CSF shows mildly elevated leukocyte counts with a lymphocytic predominance, slightly low or normal glucose and elevated or normal protein, or when the patient responds poorly to antibiotic therapy. We present the first case of BAE in children diagnosed using NGS in China. NGS of the CSF may offer better outcomes, as it can lead to earlier diagnosis and intervention. This study highlighted the important clinical significance of NGS in providing more advantageous diagnostic testing for unexplained pediatric encephalitis, especially with rare or emerging pathogens.

Disclosure statement
No potential conflict of interest was reported by the author(s).

Acknowledgements
Xia Wu and Gangfeng Yan contributed equally to this work; Xia Wu and Gangfeng Yan designed and wrote the report; Hui Yu and Hairong Gong reviewed the manuscript for its intellectual content and revised the entire work; all authors have read and approved the final manuscript.

ORCID
Hui Yu  http://orcid.org/0000-0003-1342-5537

References
[1] Visvesvara GS, Moura H, Schuster FL. Pathogenic and opportunistic free-living amoebeae: Acanthamoeba spp., Balamuthia mandrillaris, Naegleria fowleri, and Sappinia diploidea. FEMS Immunol Med Microbiol. 2007;50(1):1–26.
[2] Visvesvara GS, Martinez AJ, Schuster FL, et al. Leptomycxid ameda, a new agent of amebic meningoen-cephalitis in humans and animals. J Clin Microbiol. 1990;28(12):2750–2756.
[3] Julio Martinez A, Elia Guerra A, Garcia-Tamayo J, et al. Granulomatous amebic encephalitis: a review and report of a spontaneous case from Venezuela. Acta Neuropathol. 1994;87(4):430–434.
[4] Huang Z, Zhang C, Fang X, et al. Identification of musculoskeletal infection with non-tuberculous mycobacterium using metagenomic sequencing. J Infection. 2019;78(2):158–169.
[5] Glaser C, Schuster F, Yagi S, et al. Balamuthia amebic encephalitis-California, 1999–2007. Morb Mortal Wkly Rep. 2008;57(28):768–771.
[6] Cuevas PM, Smoje PG, Jofre ML, et al. Granulomatous amoebic meningoencephalitis by Balamuthia mandrillaris case report and literature review. Rev Chilena Infectol. 2006;23(3):237–242.
[7] Kodet R, Nohynkova E, Tichy M, et al. Amebic encepha-litis caused by Balamuthia mandrillaris in a Czech child: description of the first case from Europe. Pathol Res Pract. 1998;194(6):423–429.
[8] Bakardjieva J, Azimi PH, Ashouri N, et al. Amebic encephalitis caused by Balamuthia mandrillaris: report of four cases. Pediatr Infect Dis J. 2003;22(5):445–452.
[9] Roy SL, Atkins JT, Gnenuro R, et al. Assessment of blood-brain barrier penetration of miltefosine used to treat a fatal case of granulomatous amebic encephalitis possibly caused by an unusual Balamuthia mandrillaris strain. Parasitol Res. 2015;114(12):4431–4439.
[10] Hill CP, Damodaran O, Walsh P, et al. Balamuthia amebic meningoencephalitis and mycotic aneurysms in an infant. Pediatr Neurol. 2011;45(1):45–48.
[11] Li Q, Yang XH, Qian J. September 2004: A 6-year-old girl with headache and stiff neck. Brain Pathol. 2005;15(1):93–95.
[12] Reed RP, Cookeyarboroh CM, Jaquerry AL, et al. Fatal granulomatous amebic encephalitis caused by Balamuthia mandrillaris. Med J Aust. 1997;167(2):82–84.
[13] Tavares M, Correia Da Costa JM, Carpenter SS, et al. Diagnosis of first case of Balamuthia amebic encepha-litis in Portugal by immunofluorescence and PCR. J Clin Microbiol. 2006;44(7):2660–2663.
[14] Combs FJ, Erly WK, Valentino CM, et al. Best Cases from the AFIP: Balamuthia mandrillaris amebic meningoencephalitis. Radiographics. 2011;31(1):31–35.
[15] Valverde J, Arrese JE, Pierard GE. Granulomatous cutaneous centrofacial and meningocerebral amebiasis. Am J Clin Dermatol. 2006;7(4):267–269.
[16] Galarza M, Cuccia V, Sosa FP, et al. Pediadric granulo-matous cerebral amebiasis: a delayed diagnosis. Pediatr Neurol. 2002;26(2):153–156.
[17] Haston JC, Rostad CA, Jerris RC, et al. Prospective cohort study of next-generation sequencing as a diag-nostic modality for unexplained encephalitis in children. J Pediatric Infect Dis Soc. 2019. http://doi.org/10.1093/jpids/piz032.
[18] Deetz TR, Sawyer MH, Billman G, et al. Successful treatment of Balamuthia amoebic encephalitis: presentation of 2 cases. Clin Infect Dis. 2003;37(10):1304–1312.
[19] Moriarty P, Burke C, Mccrossin D, et al. Balamuthia mandrillaris encephalitis: survival of a child with severe meningoencephalitis and review of the literature. J Pediatric Infect Dis Soc. 2014;3(1):e4–e9.
[20] Shehab KW, Abool-Nasr K, Elliott SP. Balamuthia mandrillaris granulomatous amebic encephalitis with renal dissemination in a previously healthy child: case report and review of the pediatric literature. J Pediatric Infect Dis Soc. 2018;7(3):e163–e168.
[21] Centers for Disease Control and Prevention (CDC). Balamuthia mandrillaris transmitted through organ
transplantation-Mississippi, 2009. Morb Mortal Wkly Rep. 2010;59(36):1165–1170.

[22] Krasaekool A, Prechawit S, Chansaenroj J, et al. Fatal Balamuthia amebic encephalitis in a healthy child: a case report with review of survival cases. Korean J Parasitol. 2013;51(3):335–341.

[23] Stidd DA, Root B, Weinand ME, et al. Granulomatous amoebic encephalitis caused by Balamuthia Mandrillaris in an immunocompetent girl. World Neurosurg. 2012;78(715):e7–e12.

[24] Cope JR, Ratard RC, Hill VR, et al. The first association of a primary amebic meningoencephalitis death with culturable naegleria fowleri in tap water from a US treated public drinking water system. Clin Infect Dis. 2015;60(8):e36–e42.

[25] Kemble SK, Lynfield R, Devries AS, et al. Fatal naegleria fowleri infection acquired in Minnesota: possible expanded range of a deadly thermophilic organism. Clin Infect Dis. 2012;54(6):805–809.

[26] Farnon EC, Kokko KE, Budge PJ, et al. Transmission of Balamuthia mandrillaris by organ transplantation. Clin Infect Dis. 2016;63(7):878–888.

[27] Roy SL, Metzger R, Chen JG, et al. Risk for transmission of Naegleria fowleri from solid organ transplantation. Am J Transplant. 2014;14(1):163–171.

[28] Jayasekera S, Matin A, Sissons J, et al. Balamuthia mandrillaris stimulates interleukin-6 release in primary human brain microvascular endothelial cells via a phosphatidylinositol 3-kinase-dependent pathway. Microbes Infect. 2005;7(13):1345–1351.

[29] Rowen JL, Doerr CA, Voegl H, et al. Balamuthia mandrillaris: a newly recognized agent for amebic meningoencephalitis. Pediatr Infect Dis J. 1995;14(8):705–710.

[30] Schuster FL, Glaser C, Honarmand S, et al. Balamuthia amebic encephalitis risk, hispanic Americans. Emerg Infect Dis. 2004;10(8):1510–1512.

[31] Cope JR, Landa J, Nethercut H, et al. The epidemiology and clinical features of Balamuthia mandrillaris disease in the United States, 1974–2016. Clin Infect Dis. 2019;68(11):1815–1822.

[32] Bravo FG, Seas C. Balamuthia Mandrillaris amebic encephalitis: an emerging parasitic infection. Curr Infect Dis Rep. 2012;14(4):391–396.

[33] Schuster FL, Yagi S, Gavali S, et al. Under the radar: Balamuthia Amebic encephalitis. Clin Infect Dis. 2009;48(7):879–887.

[34] Laurie MT, White CV, Retallack H, et al. Functional assessment of 2,177 U.S. and international drugs identifies the quinoline nitroxine as a potent amoebicidal agent against the pathogen Balamuthia mandrillaris. MBIO. 2018;9(5):e02051–18.

[35] Guarner J, Bartlett J, Shieh W, et al. Histopathologic spectrum and immunohistochemical diagnosis of amebic meningoencephalitis. Mod Pathol. 2007;20(12):1230–1237.

[36] Schuster FL, Honarmand S, Visvesvara GS, et al. Detection of antibodies against free-living amoebae Balamuthia mandrillaris and Acanthamoeba species in a population of patients with encephalitis. Clin Infect Dis. 2006;42(9):1260–1265.

[37] Yagi S, Schuster FL, Visvesvara GS. Demonstration of Balamuthia and Acanthamoeba mitochondrial DNA in sectioned archival brain and other tissues by the polymerase chain reaction. Parasitol Res. 2007;102(2):211–217.

[38] Salzberg SL, Breitbart WP, Kumar A, et al. Next-generation sequencing in neuropathologic diagnosis of infections of the nervous system. Neurol Neuroimmunol Neuroinflamm. 2016;3(4):e251.

[39] Blauwkamp TA, Thair S, Rosen MJ, et al. Analytical and clinical validation of a microbial cell-free DNA sequencing test for infectious disease. Nat Microbiol. 2019;4(4):663–674.

[40] Fan S, Qiao X, Liu L, et al. Next-generation sequencing of cerebrospinal fluid for the diagnosis of neurocysticercosis. Front Neurol. 2018;9(471):1–7.

[41] Miao Q, Ma Y, Wang Q, et al. Microbiological diagnostic performance of metagenomic next-generation sequencing when applied to clinical practice. Clin Infect Dis. 2018;67(suppl 2):S231–S240.

[42] Brown JR, Bharucha T, Breuer J. Encephalitis diagnosis using metagenomics: application of next generation sequencing for undiagnosed cases. J Infect. 2018;76(3):225–240.

[43] Wilson MR, Sample HA, Zorn KC, et al. Clinical metagenomic sequencing for diagnosis of meningitis and encephalitis. N Engl J Med. 2019;380(24):2327–2340.

[44] Zysset Burri DC, Mueller N, Beuret C, et al. Genome-wide identification of pathogenicity factors of the free-living amoeba Naegleria fowleri. BMC Genomics. 2014;15(1):496–510.

[45] Wang Q, Li JM, Ji JK, et al. A case of Naegleria fowleri related primary amoebic meningoencephalitis in China diagnosed by next-generation sequencing. BMC Infect Dis. 2018;18(1):349–353.

[46] Greninger AL, Messacar K, Dunnebacke T, et al. Clinical metagenomic identification of Balamuthia mandrillaris encephalitis and assembly of the draft genome: the continuing case for reference genome sequencing. Genome Med. 2015;7:113–126.

[47] Wilson MR, Shanbhag NM, Reid MJ, et al. Diagnosing Balamuthia mandrillaris Encephalitis with metagenomic deep sequencing. Ann Neurol. 2015;78(5):722–730.